Trial Profile
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms Cosmic; COSMIC-312
- Sponsors Exelixis
- 08 Mar 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 11 Oct 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 07 Jul 2023 Status changed from recruiting to active, no longer recruiting.